



# Randomized Clinical Trial of Dialectical Behavior Therapy for Preadolescent Children With Disruptive Mood Dysregulation Disorder: Feasibility and Outcomes

Francheska Perepletchikova, PhD, Donald Nathanson, LCSW, Seth R. Axelrod, PhD, Caitlin Merrill, BA, Amy Walker, PhD, Meredith Grossman, PhD, James Rebeta, PhD, Lawrence Scahill, MSN, PhD, Joan Kaufman, PhD, Barbara Flye, PhD, Elizabeth Mauer, MS, John Walkup, MD

**Objective:** Persistent irritability and behavior outbursts in disruptive mood dysregulation disorder (DMDD) are associated with severe impairment in childhood and with negative adolescent and adult outcomes. There are no empirically established treatments for DMDD. This study examined the feasibility and preliminary efficacy of dialectical behavior therapy adapted for preadolescent children (DBT-C) with DMDD.

**Method:** Children 7 to 12 years old with DMDD (N = 43) were randomly assigned 1:1 to DBT-C or treatment as usual (TAU). The 6 domains of feasibility included recruitment, randomization, retention, attendance, participants' satisfaction, and therapist adherence. Blinded raters assessed participants at baseline, after 8, 16, 24, and 32 weeks, and at 3-month follow-up. The primary efficacy outcome was the positive response rate on the Clinical Global Impression–Improvement scale. Improvements in behavior outbursts and angry/irritable mood were assessed by the Clinical Global Impression–Severity scale.

**Results:** Mean number of participants randomized per month was  $2.53 \pm 2.72$ . Participants in DBT-C (n = 21) attended 89% of sessions compared with 48.6% in TAU

(n = 22). Eight TAU participants (36.4%) dropped out compared with none in DBT-C. Parents and children in DBT-C expressed significantly higher treatment satisfaction than those in TAU. The rate of positive response was 90.4% in DBT-C compared with 45.5% in TAU, despite 3 times as many participants in TAU receiving psychiatric medications. Remission rates were 52.4% for DBT-C and 27.3% for TAU. Improvements were maintained at 3-month follow-up. Therapists showed adherence to DBT-C.

**Conclusion:** DBT-C demonstrated feasibility in all pre-specified domains. Outcomes also indicated preliminary efficacy of DBT-C.

**Clinical trial registration information—**Adapting DBT for Children With DMDD: Pilot RCT; <http://clinicaltrials.gov/>; NCT01862549.

**Key words:** dialectical behavior therapy, preadolescent children, disruptive mood dysregulation disorder, emotion dysregulation, randomized clinical trial

**J Am Acad Child Adolesc Psychiatry** 2017;56(10):832–840.

**D**isruptive mood dysregulation disorder (DMDD) is characterized by severe and recurrent verbal and/or behavioral outbursts that are grossly out of proportion to the situation, inconsistent with developmental level, and occur at least 3 times per week for at least 1 year.<sup>1</sup> Between outbursts, children display a persistently irritable or angry mood. Prevalence rates of DMDD are estimated to be 1%, with up to 26% in clinical samples.<sup>2</sup> Impulsivity and chronic irritability are associated with severe impairment in childhood, adolescence, and adulthood, including personality disorders, substance abuse, mood disorders, and suicidality.<sup>3–5</sup> Children with DMDD also have increased rates of

service use in school, mental health systems, child welfare, and juvenile justice.<sup>1</sup>

Emotion regulation, defined as intrinsic capabilities individuals use to modulate the experience and expression of emotions based on internal or external demands,<sup>6</sup> appears to be a core deficit in DMDD.<sup>1</sup> Children with symptoms consistent with DMDD demonstrate dysfunction in neural regions implicated in emotion salience, attention, and reward processing.<sup>7,8</sup> Currently, there are no empirically established treatments for DMDD,<sup>9</sup> with current research indicating mixed results on interventions for children with severe mood dysregulation, a construct that has symptoms consistent with DMDD.<sup>10</sup> Because emotion dysregulation is associated with DMDD, interventions such as dialectical behavior therapy (DBT) that target these deficits<sup>11</sup> could be relevant to this disorder, especially with an addition of a parent training component that has been shown to decrease disruptive behaviors.<sup>12,13</sup>



Clinical guidance is available at the end of this article.

DBT is an empirically validated therapy designed to treat emotion dysregulation, suicidal thoughts and behaviors, and nonsuicidal self-injury (NSSI) associated with borderline personality disorder. DBT teaches coping skills and problem solving within a validating environment and has been successfully adapted to treat adults with depression, anxiety, substance abuse, posttraumatic stress disorder, and eating disorders<sup>14-17</sup> and adolescents with suicidality and NSSI.<sup>18</sup> Imaging studies of adults with borderline personality disorder suggest that DBT is associated with adaptive changes in the emotion processing brain circuit.<sup>19,20</sup> An open pilot trial of DBT adapted for preadolescent children (DBT-C) skills training indicated its acceptability by children and parents, a significant increase in adaptive coping skills, and a significant decrease in depressive symptoms, suicidal ideation, and problematic behaviors after treatment.<sup>21</sup>

The aims of this report are to present feasibility and preliminary efficacy results of a randomized clinical trial of DBT-C for DMDD. The 6 domains of feasibility included recruitment, randomization, retention, attendance, participants' satisfaction, and therapist adherence.<sup>22</sup> The following benchmarks were set for DBT-C feasibility: at least 2 participants per month for recruitment; dropout rate lower than 30% for retention (defined as dropped out before week 26); attendance rate of at least 70%; participants' treatment satisfaction and compliance being significantly higher than treatment as usual (TAU); and therapists' adherence score of at least 4.0. The following benchmarks were set for DBT-C preliminary efficacy: at least 20% higher response rate than for TAU; at least 50% remission rate; and significantly greater improvement in functioning than in TAU.

## METHOD

### Trial Design and Randomization Procedures

The study was a 2-arm trial with children assigned to DBT-C or TAU in a 1:1 ratio using an urn randomized procedure<sup>23</sup> that was managed by an independent statistician. Randomization was stratified by age (cutoff  $\geq 10$  years 0 months) and the presence of suicidal ideations or behaviors or NSSI. All diagnostic assessments were done by the lead authors (F.P. and D.N.) and diagnoses were derived by consensus. Independent evaluators blinded to treatment assignment monitored treatment outcomes. When un-blinding of evaluators occurred, cases were reassigned to another blinded evaluator and narratives were re-rated. Intraclass correlation was computed between the original and re-rated datasets to aid interpretation of the results. An additional clinic intake was required for the TAU group according to setting policies (e.g., psychiatric assessment and insurance verification). Participants in the 2 groups were informed of their treatment group assignment only after all the study and clinic intake procedures were completed. An additional intake for the TAU group entailed up to 2 weeks of delay in the start of treatment, whereas there was no delay required for participants in the DBT-C group. Further, participants in TAU were charged for treatment (through insurance), whereas DBT-C was provided free of charge. The study was approved by the institutional review board of the Weill Cornell Medical College (WCMC; White Plains, NY).

### Setting, Procedure, and Participants

The study was conducted at the WCMC Department of Psychiatry and NewYork-Presbyterian Hospital, Westchester Division.

Recruitment sources included referrals to the site clinic; paid advertisements in newspapers, magazines, radio, buses, and internet; referrals from pediatricians and mental health providers; and informational brochures mailed to schools and places of worship. Caregivers provided written informed consent for study participation, and children provided assent. Children were included in the study if they were 7 years 0 months to 12 years 11 months old; met criteria for DMDD; were stabilized on psychiatric medication for at least 6 weeks; and could be treated on an outpatient basis. Children were excluded if they had a documented cognitive disability ( $IQ \leq 70$ ); had a current psychotic disorder; had a pervasive developmental disorder; could not speak English; or were in state custody.

## Interventions

*DBT Adapted for Preadolescent Children.* DBT-C incorporates all 4 modes of standard outpatient DBT for adults (individual therapy, skills training, phone coaching calls, and therapist team consultation), with the addition of a parent training component.<sup>21,24,25</sup> DBT-C consisted of 32 weekly 90-minute sessions, conducted individually with each family, and divided into child counseling, parent training, and skills training with parents and children. At follow-up (weeks 33-44), up to 2 booster sessions per month were provided. Therapy was provided by PhD- and LCSW-level clinicians who were trained to adherence in DBT-C, including the lead author.

*Treatment as Usual.* Children in TAU received up to 32 weeks of individual therapy. Session duration, frequency, and treatment approach were determined by each clinician. TAU therapists were proscribed from using DBT-informed interventions, which was monitored by weekly session summary reports. TAU therapists were PhD-, MD-, and LCSW-level clinicians, including postdoctoral trainees and child psychiatry residents. Therapists were supervised weekly by senior staff.

## DBT-C Treatment Integrity

DBT-C therapists received a total of 68 hours of training.<sup>26,27</sup> Therapists were trained by the lead author who received DBT intensive training and had been approved as a DBT adherence rater by Dr. Linehan's research group. All DBT-C sessions were videotaped, and 10% were rated for treatment integrity by 1 of 3 independent raters who demonstrated treatment adherence to DBT-C and were approved as adherence raters by the lead author. The selection of sessions for review was random and stratified by therapists, participants, and treatment phases. Of the rated recordings, 20% were coded for interrater reliability. Therapists also completed self-report adherence assessments at the end of each session and participated in weekly consultation meetings.

DBT-C therapists' treatment adherence was rated using the 66-item DBT Adherence Rating Scale, reflecting 12 major DBT strategy domains.<sup>28</sup> Scores range from 0 to 5 per item and represent average strategy ratings across an entire session. A mean score of 4.0 (corresponds to 80% adherence rate) indicates adherent delivery. Interrater agreement is presumed if the difference between mean scores is no higher than 0.3.

## Assessments

Assessments were conducted at baseline, at weeks 8, 16, 24, and 32 (after treatment), and at 3-month follow-up. All assessment staff were trained and supervised by the study coordinator. Assessment duration was on average 4 hours for parents and 2 hours for children for an initial evaluation, 1.5 hours for parents and 30 minutes for children for the subsequent evaluations, and 10 minutes for weekly safety monitoring.

## Sample Characteristics

*Schedule for Affective Disorders and Schizophrenia for School Aged Children: Present and Lifetime Version.* The Schedule for Affective Disorders and Schizophrenia for School Aged Children: Present and Lifetime Version<sup>29</sup> is a semistructured psychiatric diagnostic interview revised for DSM-5 that is widely used in federally funded studies. The DMDD module was used to determine DMDD diagnosis.

*Sensory Processing Measure: Home Form.* The Sensory Processing Measure: Home Form<sup>30</sup> is a 75-item parent report that assesses functioning across 5 sensory systems on a 4-point scale. Internal consistencies range from 0.77 to 0.95 across subscales, and test-retest reliability ranges from 0.94 to 0.98.

*Services Assessment Form.* The Services Assessment Form, adapted from the Services Assessment for Children and Adolescents,<sup>31</sup> evaluates the frequency of emergency room visits, inpatient admissions, day treatment, emergency mobile psychiatric services, residential placements, and psychopharmacologic management.

*The Columbia Suicide and Self-Injury Severity Rating Scale.* The Columbia Suicide and Self-Injury Severity Rating Scale extended the Columbia Suicide Severity Rating Scale<sup>32</sup> to include items on NSSI. This instrument has strong convergent validity, sensitivity to change, predictive and incremental validity, and good internal consistency (intensity subscale  $\alpha = 0.73\text{--}0.94$ )<sup>33</sup> and has been widely used in pediatric clinical trials.

*The Hollingshead Four-Factor Index.* The Hollingshead Four-Factor Index classifies a person's socioeconomic status on a scale from 1 to 5, with higher scores indicating a higher socioeconomic status (Hollingshead AB: Four-factor index of social status. Unpublished manuscript. New Haven, CT: Yale University; 1975).

## Feasibility and Acceptability Measures

*Child and Parent Self-Reports.* The Therapy Satisfaction Questionnaire–Parent and Child Versions (TSQ)<sup>21</sup> are 7-item measures rated on a 4-point scale, with a higher score indicating higher level of satisfaction. The TSQ assesses the degree to which the program was helpful, child-friendly, and comprehensible.

## Therapist Ratings

The Therapist Satisfaction Scale (TSS) is a 15-item measure, developed for this study, rated on a 4-point scale, with a higher score indicating a higher level of therapists' satisfaction with their treatment model.

The Psychosocial Treatment Compliance Scale (PTCS) is a 17-item measure of patients' therapy participation and attendance on a 5-point scale, from "never" to "always," with higher item scores representing better compliance.<sup>34</sup> The measure has excellent test-retest reliability (0.90 for participation; 0.86 for attendance) and internal consistency (0.96 for participation; 0.87 for attendance). For this study, total compliance scores were calculated by averaging items, excluding items 5, 9, and 10, because they were not representative of processes in either treatment condition.

The Session Summary Sheet was rated by therapists at the end of each session to assess the treatment modality used (up to 9 modalities could be selected) and the duration of in-session and out-of-session contact.

The Treatment Adherence Checklist, based on the DBT Adherence Rating Scale,<sup>28</sup> is a DBT-C therapist's self-report of completion of session tasks and adherence to strategies.

## Preliminary Efficacy Measures (Rated by Independent Blinded Clinical Psychologists)

The Clinical Global Impression Scales (CGI)<sup>35</sup> are widely used measures in pediatric clinical trials.<sup>35</sup> CGI-Severity (CGI-S) is a

7-item scale ranging from a score of 1 (not ill) to 4 (meets diagnostic threshold) to 7 (requires residential/inpatient care). CGI-S for DMDD was derived by rating the severity of mood symptoms and behavioral outbursts. CGI-Improvement (CGI-I) is a 7-item scale that compares the current rating of severity with that at baseline and ranges from a score of 1 (very much improved) to 4 (no change) to 7 (very much worse). By convention, ratings of 1 (very much improved) or 2 (much improved) are used to define positive treatment response. A positive response on the CGI-I was prespecified as the main efficacy outcome, with week 32 as the end point. Remission was defined as a CGI-S score no higher than 3 (mildly ill, no impairment) rated consecutively for weeks 16, 24, and 32.<sup>36</sup> Because CGI-S is a categorical measure, the severity scores were dichotomized into "at diagnostic threshold" (score  $\geq 4$ ) and "below diagnostic threshold" (score  $\leq 3$ ).

The Children's Global Assessment Scale (CGAS)<sup>37</sup> is a measure of global functioning in children. Children are rated on a scale from 1 (extremely impaired) to 100 (superior functioning). The measure has excellent interrater reliability (intraclass coefficient 0.84) and test-retest reliability (intraclass coefficient 0.69–0.95).

## Safety Monitoring

Safety was monitored before each treatment visit using the Checklist of Adverse Incidents. Adverse incidents were reported to the participant's therapist by study personnel before the treatment session. The trial was monitored by the WCMC Data and Safety Monitoring Board.

## Analytic Plan

Sample characteristics, retention, attendance, response and remission rates per condition, medication use rates, and CGI-S outburst, mood, and global scores were compared using  $\chi^2$  and Fisher exact tests. Independent Welch 2-sample *t* tests were performed for the TSQ, TSS, PTCS, and CGAS. Paired-samples *t* tests were used to evaluate any improvements from after treatment to follow-up within groups. To assess mediation of number of sessions and average session time on CGI-I at week 32, average causal mediation effects were estimated at post hoc. All *p* values were 2-sided with statistical significance evaluated at the 0.05  $\alpha$  level. All analyses were performed in R 3.2.1 for Windows (R Foundation, Vienna, Austria). The CGI and CGAS were missing 12.79% of observations, and intent-to-treat analyses with last observation carried forward were used to estimate results.


## RESULTS

### Study Flow and Sample Characteristics

During the 16-month recruitment period, 124 participants were screened, 44 were deemed eligible, and 43 were randomized to DBT-C (21 participants) and TAU (22 participants; Figure 1). Mean randomization rate was  $2.53 \pm 2.72$  per month. Participants' characteristics are presented in Table 1.

### Interventions

DBT-C sessions were 0.5% child only, 2.8% parent only, and 96.8% parent and child, with mean session duration of  $86.55 \pm 12.76$  minutes (range 20–120), with breakdown of  $17.00 \pm 19.41$  for individual child therapy,  $29.44 \pm 17.09$  for parent training, and  $40.02 \pm 23.98$  for skills training. Mean number of out-of-session contacts (e.g., skills coaching) per

**FIGURE 1** Sample flow. Note: DBT-C = dialectical behavior therapy for preadolescent children; TAU = treatment as usual.

participant was  $8.19 \pm 5.40$ , and mean contact in minutes was  $13.58 \pm 13.22$  (range 1–90).

TAU sessions were 10.7% child only, 11.0% parent only, and 78.2% parent and child, with mean session duration of  $47.36 \pm 7.56$  minutes (range 25–95), with a breakdown of  $21.99 \pm 17.45$  for individual child therapy,  $8.18 \pm 15.50$  for parent(s) meetings, and  $17.01 \pm 17.32$  for joint sessions. Therapists' self-reported treatment approaches were 52.1% supportive, 46.3% cognitive-behavioral therapy, 42.9% parent training, 30.4% family therapy, 21.4% psychodynamic, 20.2% interpersonal, and 13.1% motivational enhancement. Mean number of out-of-session contacts per participant was  $3.60 \pm 4.14$ , and mean contact time was

$9.74 \pm 8.34$  minutes (range 1–45). TAU therapists' self-reports indicated that DBT skills were taught in only 1.2% of sessions.

#### Treatment Participation and Satisfaction

The average number of sessions per participant in DBT-C and TAU was  $28.48 \pm 3.19$  and  $15.55 \pm 8.34$ , respectively. Overall attendance in DBT-C was 89.0% compared with 48.6% for TAU (Table 2). In DBT-C, 100% of participants completed the intervention compared with 63.6% in TAU ( $p < .004$ ), because 8 participants dropped out. On average, participants who started treatment dropped out after session

**TABLE 1** Sample Characteristics at Baseline

Characteristic	DBT-C (n = 21)	TAU (n = 22)	t(df)/ $\chi^2$	p
Age (range 7–12 y), mean $\pm$ SD	9.19 $\pm$ 1.86	9.27 $\pm$ 1.64	0.15 (39.79)	.88
Boys, n (%)	12 (57.1)	12 (54.5)	0.30	.86
Hispanic, n (%)	0	5 (22.7)	5.40	.02
Caucasian, n (%)	17 (81.0)	16 (72.7)	0.41	.52
African American, n (%)	1 (4.7)	4 (18.2)	1.89	.17
Other, n (%)	2 (9.5)	1 (4.5)	0.41	.52
Asian, n (%)	0	1 (4.5)	0.98	.32
SES (range 3–5), mean $\pm$ SD	4.43 $\pm$ 0.60	4.43 $\pm$ 0.68	0.00 (39.41)	1.00
Psychiatric diagnoses, n (%)				
ADHD	7 (33.3)	10 (45.5)	0.66	.42
Anxiety disorders	8 (38.1)	4 (18.2)	2.11	.15
Enuresis or encopresis	2 (9.5)	3 (13.6)	0.18	.67
PTSD	0	1 (4.5)	0.98	.32
Tics	1 (4.7)	0	1.07	.30
1 diagnosis	7 (33.3)	6 (27.3)	0.19	.67
2 diagnoses	10 (47.6)	14 (63.6)	1.12	.29
3 diagnoses	4 (19.0)	2 (9.1)	0.89	.35
CGI Global Severity score 4, n (%)	4 (19.0)	5 (22.7)	0.09	.77
CGI Global Severity score 5, n (%)	8 (38.1)	11 (50.0)	0.62	.43
CGI Global Severity score 6, n (%)	9 (42.9)	4 (18.2)	3.10	.08
Sensory processing problems, n (%)				
Some problems in $\geq 1$ area (60T–69T)	15 (71.4)	17 (77.3)	0.53	.47
Dysfunction in $\geq 1$ area (70T–80T)	5 (23.8)	5 (22.7)	0.00	1.00
Suicidal ideations, n (%)	12 (57.1)	12 (54.5)	0.03	.86
Suicidal behaviors, n (%)	1 (4.8)	1 (4.5)	0.00	.97
NSSI urges, n (%)	10 (47.6)	8 (36.4)	0.56	.46
NSSI behaviors, n (%)	9 (42.9)	7 (31.8)	0.56	.45
Previous outpatient therapy, n (%)	16 (76.2)	20 (90.1)	1.71	.19
Special services at school, n (%)	11 (52.4)	9 (40.1)	0.57	.45
Psychiatric medications, n (%)				
Stimulants	3 (14.3)	2 (9.1)	0.28	.60
Antipsychotics	2 (9.5)	3 (13.6)	0.17	.67
Antidepressants	1 (4.8)	3 (13.6)	1.10	.32
Mood stabilizer	0	1 (4.5)	0.98	.32
Anxiolytic	0	1 (4.5)	0.98	.32
Other	1 (4.8)	1 (4.5)	0.00	.97
No medications	17 (81.0)	14 (63.6)	1.60	.21
1 medication	1 (4.8)	5 (22.7)	2.89	.09
$\geq 2$ medications	3 (14.3)	3 (13.6)	0.00	.95

Note: ADHD = attention-deficit/hyperactivity disorder; CGI = Clinical Global Impression Scale; DBT-C = dialectical behavior therapy for preadolescent children; NSSI = nonsuicidal self-injury; PTSD = posttraumatic stress disorder; SES = socioeconomic status; TAU = treatment as usual.

12 (range 6–19), with the following breakdown per month: 2 participants during month 3, 1 participant during month 4, 2 participants during month 6, and 1 participant during month 7. The most frequent reason for dropping out (87.5%) was child and/or parent refusal to participate further (Figure 1). No participants expressed dissatisfaction with randomization as the reason for dropping out. Parent treatment compliance on the PTCS and child and parent acceptability and satisfaction on the TSQ were significantly higher in DBT-C compared with TAU; however, there were no significant differences for child treatment compliance on the PTCS and therapist treatment satisfaction on the TSS (Table 2).

### DBT-C Treatment Integrity

For therapist self-reports on adherence, 3.5% of forms were missing. Therapists' self-reports of the implementation of prescribed procedures indicated 95.9% adherence to DBT-C strategies, 96.9% adherence to delivery of tasks, and completion of session topics at 93.7% for individual therapy, 95.5% for parent training, and 95.7% for skills training. Independent rating of session video recordings indicated therapists' mean overall adherence score of  $4.20 \pm 0.15$ , with  $4.23 \pm 0.17$  for individual sessions,  $4.17 \pm 0.14$  for parent training, and  $4.17 \pm 0.12$  for skills training. Interrater reliability for the total adherence level was 0.85. Mean interrater reliability for the 12 strategy domains was 0.71.

**TABLE 2** Feasibility and Acceptability Outcomes

Outcome	DBT-C			TAU			<i>t</i>	<i>df</i>	<i>p</i>	Cohen <i>d</i>	95% CI
	<i>n</i>	Mean	SD	<i>n</i>	Mean	SD					
Sessions attended, <i>n</i>	21	28.48	3.19	22	15.55	8.34	6.77	27.25	.000	2.03	1.25 to 2.81
TSQ-Child	21	22.90	5.64	18	18.39	6.26	2.35	34.63	.03	.76	0.07 to 1.45
TSQ-Parent	21	26.29	2.17	20	20.50	6.72	3.68	22.76	.001	5.44	4.49 to 6.42
PTCS-Parent	22	4.33	.61	19	3.90	.61	2.23	38.10	.03	.70	0.03 to 1.37
PTCS-Child	22	3.71	.71	19	3.30	.72	1.82	37.96	.08	.57	-0.09 to 1.23
TSS	25	45.00	10.62	21	43.71	8.83	.45	43.99	.66	.13	-0.48 to 0.74

Note: DBT-C = dialectical behavior therapy for preadolescent children; PTCS = Psychosocial Treatment Compliance Scale; TAU = treatment as usual; TSQ = Treatment Satisfaction Questionnaire; TSS = Therapist Satisfaction Scale.

### Treatment Response

Independent blinded assessors rated CGI-S and CGI-I. Agreement between independent raters was defined as the same score given between raters on temper outbursts, mood severity, and improvement. Interrater reliability was 0.82. Un-blinding of raters occurred for 20.0% of ratings. Comparison between original and re-rated observations indicated a mean intraclass correlation of 0.98 (range 0.91–1.00).

The rate of positive response on the CGI-I was 90.4% (*n* = 19 of 21) for DBT-C and 45.5% for TAU (*n* = 10 of 22;  $\chi^2 = 9.92, p = .002$ ). Almost twice as many children in DBT-C (*n* = 11, 52.4%) as in TAU (*n* = 6, 27.3%) achieved remission ( $\chi^2 = 2.83, p = .09$ ). Participants in DBT-C compared with TAU reached a significantly higher level of functioning on the CGAS (Table 3) and had significantly greater decrease in CGI-S global scores (Table 4). Four participants in TAU started new medications during the trial compared with none in DBT-C. Overall, the number of children whose treatment included psychiatric medication was 3 times higher in TAU (*n* = 12, 54.4%) than in DBT-C (*n* = 4, 19.1%;  $p = .03$ ), with 4 participants in TAU starting medications past baseline compared with none in DBT-C. Mediation analyses showed no significant average causal mediation effects on CGI-I at week 32 for average time in session (point estimate 0.02, 95% CI -0.10 to 0.15,  $p = .71$ ) or number of sessions (point estimate -0.09, 95% CI -0.20 to 0.00,  $p = .05$ ).

During the 3-month follow-up, participants in DBT-C and TAU attended  $3.57 \pm 3.11$  and  $4.00 \pm 3.14$  sessions, respectively. Positive response on the CGI-I at follow-up was 95.2% (*n* = 20 of 21) for DBT-C compared with 45.5% (*n* = 10 of 22) for TAU ( $\chi^2 = 12.63, p = .000$ ). Participants in DBT-C compared with TAU continued to maintain a significantly greater improvement in CGAS (Table 3). CGAS ratings significantly improved from posttreatment to follow-up for DBT-C ( $t_{21} = 2.64, p = .02$ ). For DBT-C, 61.9% (*n* = 13) of participants maintained the same CGI-S global level from the end of the treatment through follow-up, 28.6% (*n* = 6) decreased in severity, and 9.5% (*n* = 2) increased in severity. For TAU, 63.6% (*n* = 14) participants maintained outcomes, 13.6% (*n* = 3) decreased in severity, and 22.7% (*n* = 5) increased in severity.

### Treatment Safety

For DBT-C, no serious adverse events and 132 adverse events were reported. For TAU, there were 2 serious adverse events (non-psychiatric hospitalizations) and 98 adverse events reported. The following adverse events were reported for DBT-C and TAU: deterioration in functioning (e.g., increase in aggression), 81 and 64, respectively; suicidal ideation, 20 and 14; physical illness (e.g., headache) that interfered with functioning (e.g., missed school day, required medical attention), 21 and 13; NSSI, 10 and 2; and reports to child protective services, 0 and 5.

**TABLE 3** Children's Global Assessment Scale (CGAS) Outcomes for All Time Points

Week	CGAS						<i>t</i>	<i>df</i>	<i>p</i>	Cohen <i>d</i>	95% CI
	DBT-C			TAU							
	<i>n</i>	Mean	SD	<i>n</i>	Mean	SD					
00	21	40.67	5.37	22	44.64	9.28	-1.73	33.93	.09	-0.52	-1.16 to 0.12
08	21	52.52	13.52	22	48.68	11.47	1.00	39.26	.32	0.31	-0.33 to 0.94
16	21	61.00	16.12	22	53.00	15.39	1.66	40.65	.10	0.51	-0.13 to 1.15
24	21	64.62	16.63	22	56.41	18.47	1.53	40.87	.13	0.47	-0.17 to 1.11
32	21	69.43	15.36	22	58.00	18.08	2.24	40.47	.03	0.95	0.18 to 1.72
FU	21	75.24	14.30	22	55.77	17.94	3.94	39.76	.00	1.20	0.53 to 1.87

Note: DBT-C = dialectical behavior therapy for preadolescent children; FU = 3-month follow-up; TAU = treatment as usual.

**TABLE 4** Clinical Global Impression Scale–Severity (CGI-S) Outcomes for All Time Points

Week	CGI-S Outburst			CGI-S Mood			CGI-S Global		
	DBT-C, n (%)	TAU, n (%)	P	DBT-C, n (%)	TAU, n (%)	P	DBT-C, n (%)	TAU, n (%)	P
	≥4	≤3		≥4	≤3		≥4	≤3	
00	21 (100)	0 (0.0)	1	21 (100)	0 (0.0)	.49	21 (100)	0 (0.0)	.49
08	15 (71.4)	6 (28.6)	.49	12 (57.1)	9 (42.9)	.54	11 (52.4)	10 (47.6)	.54
16	12 (57.1)	9 (42.9)	.20	6 (28.6)	15 (71.4)	.02	6 (28.6)	15 (71.4)	.02
24	8 (38.1)	13 (61.9)	.23	6 (28.6)	15 (71.4)	.03	5 (23.8)	16 (76.2)	.03
32	6 (28.6)	15 (71.4)	.07	2 (9.5)	19 (90.5)	.01	2 (9.5)	19 (90.5)	.01
FU	5 (23.8)	16 (76.2)	.01	3 (14.3)	18 (85.7)	.00	2 (9.5)	19 (90.5)	.01

Note: DBT-C = dialectical behavior therapy for preadolescent children; FU = 3-month follow-up; TAU = treatment as usual.

## DISCUSSION

To our knowledge, this is the first published randomized clinical trial of DBT adapted for preadolescent children. This study included an active psychosocial control condition with medication management, rather than a waitlist or an open, uncontrolled design. DBT-C demonstrated feasibility and preliminary efficacy in all prespecified domains. Recruitment success was potentially related to the substantial impairment of children with DMDD and the lack of available treatment resources in the community. A credible control condition also likely improved recruitment and decreased the risk of dropping out related to randomization. Compared with other samples of children with DMDD,<sup>38,39</sup> the present sample had a much higher rate of suicidality and NSSI. We believe this discrepancy might stem from our efforts to recruit treatment-seeking youth with the highest level of symptom severity that can be treated on an outpatient basis.

Retention was high in DBT-C, with dropouts occurring only in TAU. The low dropout and high patient satisfaction rates in DBT-C are notable, specifically given that interventions with high treatment demands, such as in DBT-C, are often associated with a high dropout rate. Assessment burden did not appear to significantly affect retention. Treatment retention in TAU was challenging, although the treatment choices were based on a comprehensive evaluation, tailored to the child's needs, and permitted use of medication. The average time of dropping out from TAU was after session 12, suggesting that dropping out was not related to the randomization dissatisfaction.

Compared with TAU, DBT-C had a significantly larger percentage of children with a positive response. The high positive response rate (90.4%) is not an unusual result for DBT efficacy studies.<sup>40,41</sup> Importantly, in DBT-C, improvements were achieved without the need to start new psychiatric medications; only children who were on psychiatric medications at baseline continued to receive psychopharmacologic management. The parent component of DBT-C (e.g., training parents to validate and to model, elicit, and reinforce skills use) might have contributed to retention, positive outcomes, and no reports to child protective services. The DBT-C model presumes the development of a validating and change-ready environment as the main therapeutic ingredient. Because parent involvement was high in TAU, the differences in the content of training between conditions might have contributed to outcomes.

There are several limitations. First, DBT-C was a manual-based intervention, whereas TAU did not adhere to a specific manual. However, TAU therapists were supervised closely for each treatment plan. Further, therapists' levels of satisfaction with provided treatments were similar between conditions, suggesting that therapists' enthusiasm about the provided interventions might not have contributed to the obtained results. Second, there was a substantial difference between the number of attended sessions and session lengths between conditions. However, these factors did not

appear to affect outcomes. Third, participants in DBT-C received therapy free of charge. In contrast, participants in TAU were charged for treatment (through insurance). This structural difference might have affected the dropout rate in TAU, although participants did not state payment for services as a reason for dropping out. A confirmatory efficacy trial is needed with a more structured TAU, with built-in strategies for retention and without requirement for payment. Further research needs to examine the effects of DBT-C on specific outcomes, including depression and anxiety, and evaluation of mediating factors, including emotion regulation, creation of validating environment, and treatment duration. &



### Clinical Guidance

- DBT-C can be used with preadolescent children (7–12 years of age) with severe emotional and behavioral dysregulation, including suicidality and NSSI.
- Children and their parents find DBT-C acceptable, understandable, interesting, child-friendly, and helpful.
- Parental active participation and compliance with treatment could be more important than a child's compliance and engagement for symptom relief.
- The content of parent training can affect outcomes. Teaching parenting techniques alone (e.g., reinforcement, extinction, punishment, shaping) might not be as effective as in combination with training parents on how to validate (which serves as a foundation for change), create a change-ready environment (e.g., model skills use, improve parent–child relationship, daily practice of skills with children), and achieve emotion regulation needed to successfully implement behavior modification techniques (e.g., ability to tolerate escalation during extinction bursts).
- Symptom relief can be achieved without supplemental psychopharmacologic interventions.
- Although DBT-C has high treatment demands, rapid improvement in functioning could help maintain engagement and prevent dropping out.

Accepted August 3, 2017.

This article was reviewed under and accepted by Ad Hoc Editor Argyris Stringaris, MD, PhD, MRCPsych.

Drs. Perepletchikova, Flye, Walkup, and Mr. Nathanson are with Weill Cornell Medicine and New York-Presbyterian Hospital, White Plains, NY. Dr. Axelrod is with the Yale University School of Medicine, New Haven, CT. Ms. Merrill is with University of California–Santa Barbara. Dr. Walker is with Cognitive Behavioral Consultants, White Plains, NY. Dr. Grossman is with Evidence-Based Psychology, New York. Dr. Rebata and Ms. Maurer are with Weill Cornell Medicine. Dr. Scahill is with Emory University, Marcus Autism Center, Atlanta, GA. Dr. Kaufman is with the Center for Child and Family Traumatic Stress, Kennedy Krieger Institute, Johns Hopkins School of Medicine, Baltimore, MD.

Grant support: K99/RO0 MH087627 NIMH (PI - F. Perepletchikova); UL1 RR000457 NCATS (partial support for F. Perepletchikova); UL1-TR000457-06 NCATS (partial support for E. Maurer).

Ms. Maurer served as the statistical expert for this research.

The authors thank Tami Frankforter, BS, Yale University School of Medicine, for her help with data management and Melissa Kivell, BS, Kiera Bloch, MPH, and Sara Letizia, BA, for their assistance in data collection.

Disclosure: Drs. Perepletchikova and Axelrod have served as trainers for Linehan's DBT treatment dissemination company and have a contract with Guilford Press to convert the DBT-C treatment manual into a book. Dr. Scahill has served as a consultant to Neuren, Bracket, Roche, Shire, Supernus, and the Tourette Association of America. He has been a speaker for the Tourette Syndrome–Centers for Disease Control and Prevention outreach educational programs. He has received royalties from Oxford and Guilford. Dr. Walkup has received past research support from the National Institute of Mental Health for federally funded studies including free drug and placebo from Pfizer in 2007 to support the Child Adolescent Anxiety Multimodal study; free medication from Abbott in 2005 for the Treatment of the Early Age Media study; free drug and placebo from Eli Lilly and Co. in 2003 for the Treatment of Adolescents with Depression study. He currently receives research support from the Tourette Association of America and The Hartwell Foundation. He has served as an unpaid advisor to the Anxiety Disorders Association of America and the Trichotillomania Learning Center. He has received honoraria and travel expenses for speaking engagements and meetings sponsored by the Tourette Association of America. He has received royalties from Guilford Press and Oxford University Press for multi-author books published about Tourette syndrome and from Wolters Kluwer for CME activity on childhood anxiety. He has served as a paid speaker for the Tourette Syndrome - Center for Disease Control and Prevention outreach educational programs, the American Academy of Child and Adolescent Psychiatry, and the American Psychiatric Association. Drs. Walker, Grossman, Rebata, Kaufman, Flye, Mr. Nathanson, Ms. Merrill, and Ms. Maurer report no biomedical financial interests or potential conflicts of interest.

Correspondence to Francheska Perepletchikova, PhD, Child and Adolescent Psychiatry Division, Outpatient Department, Weill Cornell Medical College, 21 Bloomingdale Road, Suite 110A, White Plains, NY 10605; e-mail: frp2008@med.cornell.edu

0890-8567/\$36.00/©2017 American Academy of Child and Adolescent Psychiatry

<http://dx.doi.org/10.1016/j.jaac.2017.07.789>

### REFERENCES

1. Copeland WE, Angold A, Costello EJ, Egger H. Prevalence, comorbidity, and correlates of DSM-5 proposed disruptive mood dysregulation disorder. *Am J Psychiatry*. 2013;170:173-179.
2. Baweja R, Mayes SD, Hameed U, Waxmonsky JG. Disruptive mood dysregulation: current insights. *Neuropsychiatr Dis Treat*. 2016;12:2115-2124.
3. Althoff RR, Verhulst FC, Rettew DC, Hudziak JJ, van der Ende J. Adult outcomes of childhood dysregulation: a 14-year follow-up study. *J Am Acad Child Adolesc Psychiatry*. 2010;49:1105-1116.
4. Okado Y, Bierman KL. Differential risk for late adolescent conduct problems and mood dysregulation among children with early externalizing behavior problems. *J Abnorm Child Psychol*. 2015;43:735-747.
5. Pickles A, Aglan A, Collishaw S, Messer J, Rutter M, Maughan B. Predictors of suicidality across the life span: the Isle of Wight study. *Psychol Med*. 2010;40:1453-14667.
6. Sheppes G, Suri G, Gross JJ. Emotion regulation and psychopathology. *Annu Rev Clin Psychol*. 2015;11:379-405.
7. Brotman MA, Kircanski K, Leibenluft E. Irritability in children and adolescents. *Annu Rev Clin Psychol*. 2017;13:317-341.
8. Leibenluft E. Pediatric irritability: a systems neuroscience approach. *Trends Cogn Sci*. 2017;21:277-289.
9. Tourian L, LeBoeuf A, Breton J, *et al*. Treatment options for the cardinal symptoms of disruptive mood dysregulation disorder. *J Can Acad Child Adolesc Psychiatry*. 2015;24:41-54.

10. Waxmonsky JG, Waschbusch DA, Belin P, *et al.* A randomized clinical trial of integrative group therapy for children with severe mood dysregulation. *J Am Acad Child Adolesc Psychiatry.* 2016;55:196-207.
11. Linehan MM, Comtois KA, Murray AM, *et al.* Randomized controlled trial and follow-up dialectical behavior therapy vs. therapy by experts for suicidal behaviors and borderline personality disorder. *Arch Gen Psychiatry.* 2006;63:757-766.
12. Dretzke J, Davenport C, Frew E, *et al.* The clinical effectiveness of different parenting programmes for children with conduct problems: a systematic review of randomized controlled trials. *Child Adolesc Psychiatry Ment Health.* 2009;3:1-10.
13. Sukhodolsky DG, Smith SD, McCauley SA, Ibrahim K, Piasecka JB. Behavioral interventions for anger, irritability and aggression in children and adolescents. *J Child Adolesc Psychopharmacol.* 2016;26:58-64.
14. Bohus M, Dyer AS, Priebe K, *et al.* Dialectical behavior therapy for post-traumatic stress disorder after childhood sexual abuse in patients with and without borderline personality disorder: a randomized controlled trial. *Psychother Psychosom.* 2013;82:221-233.
15. Linehan MM, Dimeff LA, Reynolds SK, *et al.* Dialectical behavior therapy versus comprehensive validation therapy plus 12-step for the treatment of opioid dependent women meeting criteria for borderline personality disorder. *Drug Alcohol Depend.* 2002;67:13-26.
16. Lynch TR, Morse JQ, Mendelson T, Robins CJ. Dialectical behavior therapy for depressed older adults: a randomized pilot study. *Am J Geriatr Psychiatry.* 2003;11:33-45.
17. Salbach-Andrae H, Bohnkamp I, Pfeiffer E, Lemkul U, Miller AL. Dialectical behavior therapy of anorexia and bulimia nervosa adolescents: a case series. *Cogn Behav Pract.* 2008;15:415-425.
18. Mehlum L, Tormoen A, Ramberg M, *et al.* Dialectical behavior therapy for adolescents with repeated suicidal and self-harming behavior: a randomized trial. *J Am Acad Child Adolesc Psychiatry.* 2014;53:1082-1091.
19. Goodman M, Carpenter D, Tang CY, *et al.* Dialectical behavior therapy alters emotion regulation and amygdala activity in patients with borderline personality disorder. *J Psychiatr Res.* 2014;57:108-116.
20. Schnell K, Herpertz SC. Effects of dialectic-behavioral-therapy on the neural correlates of affective hyperarousal in borderline personality disorder. *J Psychiatr Res.* 2007;4:837-847.
21. Perepletchikova F, Axelrod SR, Kaufman J, Rounsaville BJ, Douglas-Palumberi H, Miller AL. Adapting dialectical behavior therapy for children: towards a new research agenda for paediatric suicidal and non-suicidal self-injurious behaviors. *Child Adolesc Ment Health.* 2011;16:116-121.
22. Leon AC, Davis LL, Kraemer HC. The role and interpretation of pilot studies in clinical research. *J Psychiatr Res.* 2011;45:626-629.
23. Stout RL, Wirtz PW, Carbonari JP, Del Boca FK. Ensuring balanced distribution of prognostic factor in treatment outcome research. *J Stud Alcohol.* 1994;12:70-75.
24. Perepletchikova F, Goodman G. Two approaches to treating pre-adolescent children with severe emotional and behavioral problems: Dialectical behavior therapy adapted for children and mentalization-based child therapy. *J Psychother Integr.* 2014;24:298-312.
25. Perepletchikova F. Dialectical behavior therapy for pre-adolescent children. In: Swales M, ed. *The Oxford Handbook of Dialectical Behavior Theory.* Oxford, UK: Oxford University Press; 2017. <http://dx.doi.org/10.1093/oxfordhb/9780198758723.013.25>.
26. Perepletchikova F, Treat T, Kazdin AE. Treatment integrity in psychotherapy research: analysis of the studies and examination of the associated factors. *J Consult Clin Psychol.* 2007;75:829-841.
27. Perepletchikova F. *Treatment Integrity in Treatment Outcome Research: Adequacy of Procedures, Associated Factors, Implications for Research and Practice, Guidelines and Recommendations.* Dusseldorf, Germany: Lambert Academic Publishing; 2009.
28. Linehan MM, Korslund KE. *Dialectical Behavior Therapy Adherence Manual.* Seattle: University of Washington; 2003.
29. Kaufman J, Birmaher B, Axelson D, Perepletchikova F, Brent D, Ryan N. *Schedule for Affective Disorders and Schizophrenia for School Aged Children (6-18 Years)—Lifetime Version for DSM-V.* Baltimore, MD: Kennedy Krieger Institute; 2016; [https://www.kennedykrieger.org/sites/default/files/community\\_files/ksads-dsm-5-screener.pdf](https://www.kennedykrieger.org/sites/default/files/community_files/ksads-dsm-5-screener.pdf). Accessed August 2, 2018.
30. Parham LD, Ecker C, Miller Kuhaneck H, Henry DA, Glennon TJ. *Sensory Processing Measure (SPM): Manual.* Los Angeles, CA: Western Psychological Services; 2007.
31. Horwitz SM, Hoagwood K, Stiffman AR, *et al.* Reliability of the services assessment for children and adolescents. *Psychiatr Serv.* 2001;52:1088-1094.
32. Posner K, Melvin GA, Stanley B, Oquendo MA, Gould M. Factors in the assessment of suicidality in youth. *CNS Spectr.* 2007;12:156-162.
33. Posner K, Brown GK, Stanley B, *et al.* The Columbia-Suicide severity rating scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults. *Am J Psychiatry.* 2011;168:1266-1277.
34. Tsang HW, Fung KM, Corrigan PW. Psychosocial treatment compliance scale for people with psychotic disorders. *Aust N Z J Psychiatry.* 2006;40:561-569.
35. Guy W. The Clinical Global Impression Scale. In: *ECDEU Assessment Manual for Psychopharmacology—Revised.* Rockville, MD: US Department of Health, Education and Welfare, ADAMHA, NIMH Psychopharmacology Research Branch; 1976:218-222.
36. Busner J, Targum SD. The Clinical Global Impression Scale: applying a research tool in clinical practice. *Psychiatry.* 2007;4:28-37.
37. Shaffer D, Gould MS, Brasic J, *et al.* A Children's Global Assessment Scale (CGAS). *Arch Gen Psychiatry.* 1983;40:1228-1231.
38. Freeman AJ, Youngstrom EA, Youngstrom JK, Findling RL. Disruptive mood dysregulation disorder in a community mental health clinic: prevalence, comorbidity and correlates. *J Child Adolesc Psychopharmacology.* 2016;26:123-130.
39. Mulraney M, Schilpzand EJ, Hazell P, *et al.* Comorbidity and correlates of disruptive mood dysregulation disorder in 6-8-year-old children with ADHD. *Eur Child Adolesc Psychiatry.* 2016;25:321-330.
40. Beckstead DJ, Lambert MJ, DuBose AP, Linehan MM. Dialectical behavior therapy with American Indian/Alaska Native adolescents diagnosed with substance use disorders: combining an evidence based treatment with cultural, traditional, and spiritual beliefs. *Addict Behav.* 2015;51:84-87.
41. Nelson-Gray RO, Keane SP, Hurst RM, *et al.* A modified DBT skills training program for oppositional defiant adolescents: promising preliminary findings. *Behav Res Ther.* 2006;44:1811-1820.